Product news

Share this article:
Boehringer Ingelheim announced that the European Commission has granted marketing approval for its novel, direct thrombin inhibitor, Pradaxa (dabigatran etexilate) in all 27 EU member states. It is anticipated that Pradaxa will be launched in Germany and the UK in the coming weeks. Pradaxa is approved for the prevention of venous thromboembolic events in adults who have undergone elective total hip or total knee replacement surgery.
 
Wyeth and Progenics Pharmaceuticals received Canadian marketing approval for Relistor, a drug for the treatment of opioid-induced constipation in patients with advanced illness. Wyeth expects the drug to be available to patients in Canada within 60 days. The companies anticipate an FDA decision on Relistor by the end of April.
Share this article:

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.